RecruitingNCT07367880
The Monument Test : A New Tool for Assessing the Ability to Name and Identify Unique Entities. (TeDIMO)
Sponsor
University Hospital, Grenoble
Enrollment
220 participants
Start Date
Feb 23, 2026
Study Type
OBSERVATIONAL
Conditions
Summary
The goal of this study is to show a significant difference in performance between 2 groups of participants (healthy elderly people vs. people with Alzheimer Disease) in an identification and naming task involving famous monuments.
Eligibility
Min Age: 50 YearsMax Age: 95 Years
Inclusion Criteria8
- Alzheimer's disease:
- Age ≥ 50 years and older
- Possible or probable diagnosis of Alzheimer's disease according to the revised criteria of Mac Khann et al., 2011.
- Score 18≤ MMSE ≤26
- Controls:
- Age ≥ 50 years and older
- MMSE score ≥ 26 For all subjects
- No objection from the participant
Exclusion Criteria10
- Alzheimer's disease:
- Persons referred to in Articles L1121-5 to L1121-8 of the CSP
- Controls:
- Memory complaints
- Persons referred to in Articles L1121-5 to L1121-8 of the CSP For all subjects
- Significant neurological or psychiatric history
- Taking psychotropic medication (neuroleptics)
- Poor command of the French language, comprehension difficulties
- Significant hearing or visual impairments (diplopia, nystagmus, scotoma, etc.)
- Insufficient exposure to the media and/or socio-cultural knowledge (questionnaire) ; Deficit in face recognition (Benton Face Recognition Test)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERIdentification and naming task
Task of identification and naming of landmarks and celebrities
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07367880
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
NCT06976216106 locations
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
NCT065481911 location
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
NCT06976203124 locations
Safety Assessment of Leronlimab and Its Effect on Brain Inflammation in Alzheimer's Disease
NCT075533381 location